Revolution Medicines SVP & General Counsel Sells 765 Shares Under Rule 10b5-1 Plan

Executive Summary

On September 29, 2026, Jeff Cislini, Senior Vice President & General Counsel of Revolution Medicines, Inc. ($RVMD), reported an open market sale of 765 shares of common stock. The transaction took place on September 25, 2026, at an average execution price of $207.3201 per share, totaling approximately $158,600.

Key Transaction Details

• Security: Common Stock
• Transaction Code: S (Open market or private sale)
• Shares Sold: 765
• Price per Share: $207.3201
• Gross Proceeds: $158,599.88
• Post-Transaction Holdings: 51,776 shares (including 37,088 restricted stock units)

Context & Trading Plan

The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2026. This pre-scheduled mechanism indicates routine, programmatic portfolio management rather than a discretionary, thesis-driven liquidation.

Materiality & Market Impact

The disposition represents approximately 1.46% of Cislini's direct holdings prior to the transaction (765 out of 52,541 total shares/RSUs). Due to the pre-scheduled 10b5-1 framework and modest transaction size relative to the insider's aggregate holdings, the market significance of this trade is categorized as Low.